-+ 0.00%
-+ 0.00%
-+ 0.00%

Goldman Sachs Initiates Coverage On Corvus Pharmaceuticals with Buy Rating, Announces Price Target of $40

Benzinga·04/17/2026 11:41:22
Listen to the news
Goldman Sachs analyst Paul Choi initiates coverage on Corvus Pharmaceuticals (NASDAQ:CRVS) with a Buy rating and announces Price Target of $40.